Study of sinus disease in young children with cystic fibrosis
Part of Brain & nervous system, Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study looks at sinus problems in young children with cystic fibrosis. One group of children starts a new medicine called a highly effective modulator (like Trikafta), and the other group does not take this medicine. The goal is to see how the medicine affects sinus health over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has been diagnosed with cystic fibrosis.
- Your child is between 2 and 8 years old at the first study visit.
- If your child is in the modulator group, they must have a type of CF gene change that allows them to take Trikafta or Kalydeco, and their doctor plans to start the medicine.
- If your child is in the control group, they cannot take Trikafta or Kalydeco because of their gene change, or their doctor has decided not to start it.
- Your child has not taken Trikafta or Kalydeco in the last 6 months.
- Your child has not had sinus surgery in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether ivacaftor can improve chronic sinus disease caused by problems with a specific body channel called CFTR. It may help some people whose sinus imaging, cultures, and prior sinus surgery match the study’s criteria.
This study looks at how well a highly effective cystic fibrosis (CF) medicine works in infants and young children, and what biological changes it causes. It may help families understand whether the medicine improves CF function and related measures early in life.
This study looks at how endoscopic sinus surgery affects people with cystic fibrosis who have ongoing sinus problems even after medical treatments. It may help doctors understand whether surgery plus ongoing care improves symptoms and quality of life.
This study tests a streamlined approach to managing sudden lung symptoms (pulmonary exacerbations) in children with cystic fibrosis. It aims to see if a simpler treatment plan works as well as standard care, which could mean less time in the hospital and fewer disruptions to daily life.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
Hear when a new Cystic Fibrosis in Children trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.